tbuckley/cabot-search huggingface dataset:
Abstract P2-01-27: In patients with micrometastatic in sentinel lymph node biopsies, involvement of the non-sentinel lymph nodes cannot be predicted by clinicopathological variables
Authors: Muhammad N Chauhan, Rajiv V Dave, Mauria Ghaus, Sana Ahmad, Craig Sayers, Zbigniew Kryjak, Deedar Ali
Journal: Cancer Research (2015)

Abstract Background: The Sentinel Lymph Node Biopsy (SLNB) procedure is recognised to be an accurate method of staging the axilla in patients with early stage breast cancer. There remains a debate as to whether patients with micrometastases should undergo completion axillary lymph node dissection (CALND). We aimed to assess the indicators for positive non-sentinel lymph nodes (n-SLN) following CALND. Methods: We retrospectively analysed our experience of SNLB between July 2008 to July 2013. A total of 1152 breast cancer patients underwent SLNB based on lymphoscintigraphy, intra-operative gamma probe detection, and blue dye mapping using 99mTc-nanocolloid and Patent Blue V injected peri-areola. Statistical analysis was performed using Fisher’s exact and c2 for categorical data. Results: Out of 1152 SLNB biopsies performed, 224 (19.5%) were positive for metastatic disease; macrometastases in 150 (67%), micrometastases in 72 (32%) and ITC in 2. CALND was not performed in 20 cases (9 macrometastases, 10 micrometastases, and 1 ITC), largely due to concerns regarding fitness for anesthesia. Macrometastases on SNLB were more likely to predict positive n-SLN on ANC {macrometastases; 39/141(27.7%) vs micrometastases; 9/62 (14.5%), p=0.029}. On univariate analysis, positive n-SLN in CALND for patients with micrometastases on SLNB was not predicted by grade (G0-G2; 6/43, and G3; 3/19, p=0.565), size of primary breast tumour (&amp;lt;40mm; 8/58, 340mm; 1/4, p=0.475), lymphovascular invasion (5/30 vs 4/31, p=0.503), age (&amp;lt;50 years; 3/24 vs 350 years; 6/38, p=0.496), or number of positive SLNB (all patients had &amp;lt;2 positive nodes on SLNB). Recurrences were detected in 4 patients, of which 1 was in a patient with micrometastases on SLNB. Out of the 4 recurrences, 3 were distant (liver and bone) and one was locoregional, with new disease in the contralateral breast). Conclusion In our series, 14.5% (9/62) of patients with micrometastases had positive n-SLB on CALND, which was not predicted by any clinicopathological characteristics. We have recently changed our practice toward not routinely offering CALND in patients with micrometastases, in keeping with current vogue. However, it is important to inform our patients that 14.5% of patients with micrometastases on SLNB may have positive n-SLN. Citation Format: Muhammad N Chauhan, Rajiv V Dave, Mauria Ghaus, Sana Ahmad, Craig Sayers, Zbigniew Kryjak, Deedar Ali. In patients with micrometastatic in sentinel lymph node biopsies, involvement of the non-sentinel lymph nodes cannot be predicted by clinicopathological variables [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-01-27.
PENICILLIN TREATMENT OF STREPTOCOCCAL PHARYNGITIS
Authors: J P LOGE, E D KILBOURNE
Journal: Annals of Internal Medicine (1948)

ExcerptDuring recent years the commonplace and ubiquitous entity of "streptococcus sore throat" has been the object of intensive study. Interest in hemolytic streptococcal pharyngitis has been heightened both by its importance as an acute epidemic disease during the war, and by its current recognition as a primary excitant of rheumatic fever and glomerulonephritis. Coincidentally, the discovery of effective antistreptococcal agents has aroused interest in the treatment of the acute disease and the prevention of its sequelae.The critical appraisal of any treatment demands the establishment of strict control groups and accurate delineation of the natural history of the disease in...
Abstract 15780: Aortic Valve Replacement With Sutureless Perceval S Prosthesis: An European Multicenter, Prospective Trial
Authors: Malakh Shrestha, Thierry Folliguet, Bart Meuris, Alain Dibie, Christoph Bara, Samir Sarikouch, Marie-Christine Herregods, Klaus Hoeffler, Nawid Khaladj, Sven Peterss, Christian Hagl, Francesco Madonna, Alain Prat, Daniel Duveau, Heinz Jakob, Axel Laczkovics, Mario Stalder, Thierry Carrel, Willem Flameng, Francois Laborde, Axel Haverich
Journal: Circulation (2011)

OBJECTIVES: This clinical trial was designed to evaluate the safety and effectiveness of aortic valve replacement (AVR) with Perceval S (Sorin (R)) in patients ≥ 75 years of age. The Perceval S sut...
Ureteral Stricture as a Cause of Attempted Suicide
Authors: Mitchell Bernstein
Journal: Annals of Internal Medicine (1929)

Article1 January 1929Ureteral Stricture as a Cause of Attempted SuicideMITCHELL BERNSTEIN, M.D.MITCHELL BERNSTEIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-2-7-682 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn view of Hunner's teaching of the possibility of ureteral stricture simulating a variety of acute and chronic abdominal conditions, the following case report of attempted suicide due to the pain of an ureteral stricture, I believe, is of more than academic interest.Case Report:—C. R., aged 44, female, married, was admitted to the Jewish Hospital on May 2, 1928, in an unconscious condition as a consequence of illuminating gas poisoning, the gas being taken with suicidal intent. After resuscitation, the patient stated that she attempted suicide since she has suffered unbearable abdominal pain, from which she was unable... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, Pa.*From the Medical Service of Dr. Bernard Kohn, Jewish Hospital, Philadelphia, Pa. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1929Volume 2, Issue 7Page: 682-684KeywordsAbdominal painMedical servicesResuscitationSuicide ePublished: 1 December 2008 Issue Published: 1 January 1929 PDF downloadLoading ...
Abstract 2954: Short-term Effects of High Dose Idebenone on Left Ventricular Mass and Function in a Pediatric Cohort with Friedreich’s Ataxia
Authors: Jonathan F Plehn, Keren Hasbani, Ken Horton, Inez Ernst, Andrew E Arai, Nicholas A Di Prospero
Journal: Circulation (2008)

Background: Early mortality in Friedreich’s Ataxia (FA) is believed to commonly result from an underlying hypertrophic cardiomyopathy which may be caused by increases in reactive oxygen species. Antioxidant therapy could result in slowing of disease progression or regression of left ventricular mass (LVM). Methods: We tested the hypothesis that high dose idebenone could lead to regression of LVM and LV functional improvement in 48 pediatric subjects with genetically-confirmed FA (23 females, 25 males, mean age=13.4 years) randomly assigned to weight-stratified low (4 – 8 mg/kg), medium (10–20 mg/kg) or high (30–50 mg/kg) doses of idebenone or placebo. Cardiac magnetic resonance imaging (MRI) and echocardiographic (echo) two-dimensional and Doppler analysis blinded to treatment assignment were performed at baseline and after 6 months of therapy. Results: At baseline, increased LVM indexed by height 2.7 was observed in 44%, LV concentric remodeling (relative wall thickness &gt;0.39) in 83% and impaired early relaxation by Doppler tissue velocity (E’) in 88% of subjects as determined by age-adjusted, normative echo data. MRI-determined LVM (n=45 subjects) was inversely related to measures of LV relaxation including E’ (p&lt;0.0001), color Doppler flow propagation (p&lt;0.007) and isovolumic relaxation time (p&lt;0.005) but not mitral deceleration time. LVM also correlated with peak lateral systolic tissue velocity (p=0.002) but not LV ejection fraction. At 6 months combined, idebenone-assigned subjects demonstrated a 1.3 ± 1.6 % reduction of LVM vs. baseline which compared to an 8.9 ± 4.0% LVM increase in placebo subjects (p=.007). By Fisher’s test, LVM regression was observed only in the high and intermediate dose groups (p≤0.05 and p≤0.01) with a trend toward regression in the low dose group (p=0.056). No effects on diastolic relaxation or systolic functional parameters were observed after 6 months of idebenone treatment. Conclusions: Hypertrophic cardiomyopathy and associated diastolic functional impairment is highly prevalent in pediatric FA patients with moderate neurologic impairment. Short term treatment with high dose idebenone appears to result primarily in blunting of LV mass progression but not to detectable improvements in LV function.
Enabling Key Applications with the SOLiD™ System
Authors: Robert Nutter
Journal: Clinical Cancer Research (2007)

AACR Centennial Conference: Translational Cancer Medicine-- Nov 4-8, 2007; Singapore

CN02-03 

The decreasing cost of sequencing is driving the development of genome-wide applications based on sequence data. Instead of using different platforms for applications such as gene expression, genotyping and sequencing, it is becoming possible to use sequencing as the universal currency for most, if not all, genetic analysis. The SOLiD™ System is a ligation-based, massively parallel sequencing system that can currently generate in excess of 3 Gb of DNA sequence per run. Investigators can elect to use either fragment or mate-paired libraries and can run one or multiple samples at a time. We are taking advantage of the high throughput, accuracy, and scalability of the SOLiD™ System to collaborate with a number of scientific groups to develop a range of applications. . My talk will provide current results demonstrating the power of sequencing fragment or mate paired libraries to provide data for a number of important genetic analysis applications, including transcriptome analyses, CpG methylation patterns, nucleosome phasing as well as large insertion/deletion identification and mapping.
Osteoporosis and osteopenia: implications for periodontal and implant therapy
Authors: Joan Otomo‐Corgel
Journal: Periodontology 2000 (2012)

Abstract How does low bone mineral density alter treatment decisions? Osteoporosis and osteopenia are major health care issues that may impact on periodontal and implant therapy. Because of the prevalence of osteoporosis, understanding its etiology and the current treatment regimens for patients with low bone mineral density is essential for dental professionals. Millions of patients are now taking medications for the treatment of osteoporosis, and periodontists should be aware of the many medication options that are prescribed. The most frequently prescribed drugs are the bisphosphonates. It is important to be aware that bisphosphonates are not all the same, and patient responses to treatment may vary depending on which bisphosphonates they are taking. Due to recent concerns about bisphosphonate‐induced osteonecrosis of the jaw, this paper provides guidance to help the clinician regarding decision‐making about preventive and interventional dental treatment when their patient has been prescribed a bisphosphonate. An understanding of current bisphosphonates, their uses, their structural differences and their intended actions helps to improve clinical decision‐making. Current knowledge regarding the effects of osteoporosis/osteopenia on periodontal diseases and alveolar bone loss is inconclusive. It is certainly clear that bisphosphonates are not indicated as an adjunctive treatment as part of periodontal therapy because of the risk of osteonecrosis. Regarding implant placement, there are no convincing data that dental implant placement is contraindicated in the osteoporotic patient. However, patients should understand the small risk of compromised bone healing following implant placement if the patient has been taking bisphosphonates. Due to the risks of osteonecrosis, dental clinicians should work closely with their medical colleagues prior to the physician prescribing oral bisphosphonates. Ideally, optimal periodontal and dental health should be established before the patient commences bisphosphonate therapy.
Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma
Authors: James Larkin, Christopher D. Lao, Walter J. Urba, David F. McDermott, Christine Horak, Joel Jiang, Jedd D. Wolchok
Journal: JAMA Oncology (2015)

<h3>Importance</h3> The anti–PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type<i>BRAF</i>kinase vs patients with tumors having mutant<i>BRAF</i>has not systematically been explored in a large dataset. <h3>Objective</h3> To evaluate the efficacy and safety of nivolumab in patients with wild-type<i>BRAF</i>and mutant<i>BRAF</i>metastatic melanoma. <h3>Design, Setting, and Participants</h3> This was a retrospective analysis of data pooled from 4 clinical trials of nivolumab in 440 adult patients with unresectable stage III or stage IV melanoma, who had been tested for<i>BRAF</i>mutational status while participating in one of the studies. <h3>Intervention</h3> The investigational drug, nivolumab, was administered intravenously to study participants over a 60-minute period, at doses of 0.1, 0.3, 1.0, 3.0, or 10.0 mg/kg every 2 weeks until disease progression, discontinuation owing to adverse events, withdrawal, or end of study. Most patients (83%) received nivolumab at a dosage of 3 mg/kg. <h3>Main Outcome and Measure</h3> Best overall response by modified World Health Organization or Response Evaluation Criteria In Solid Tumors criteria and safety profile. <h3>Results</h3> Of a total of 440 patients from 4 nivolumab clinical trials included in the analysis, 334 were<i>BRAF</i>wild-type and 106 were positive for<i>BRAF</i>V600 mutation. With the exception of prior<i>BRAF</i>inhibitor therapy, the demographics were well balanced between the 2 cohorts. In patients evaluable for response, the objective response rates were 34.6% (95% CI, 28.3-41.3) for the 217 patients with wild-type<i>BRAF</i>status and 29.7% (95% CI, 19.7-41.5) for the 74 with mutant<i>BRAF</i>status. The objective response rates did not seem to be affected by prior<i>BRAF</i>inhibitor therapy, prior ipilimumab therapy, or PD-L1 status of the tumor. The median duration of objective response was 14.8 months (95% CI, 11.1-24.0 months) for wild-type<i>BRAF</i>and 11.2 months (95% CI, 7.3-22.9 months) for mutant<i>BRAF</i>. Median time to objective response was 2.2 months in both patient groups. The incidence of treatment-related adverse events of any grade was 68.3% in the wild-type<i>BRAF</i>group and 58.5% in the mutant<i>BRAF</i>group, with grade 3 or 4 adverse events in 11.7% and 2.8% of patients, respectively. Treatment-related AEs of any grade that occurred in at least 5% of patients in either group were fatigue, pruritus, rash, and diarrhea. <h3>Conclusions and Relevance</h3> The results of this retrospective analysis suggest that nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant<i>BRAF</i>, regardless of prior<i>BRAF</i>inhibitor or ipilimumab treatment.
Abstract 11514: Adverse Events in Patients With Rheumatic Mitral Valve Disease in Sinus Rhythm
Authors: Hyun-Jin Kim, Goo-Yeong Cho, Yong-Jin Kim, Hyung-Kwan Kim, Seung-Pyo Lee, Hack-Lyoung Kim, Jin Joo Park, Yeonyee E Yoon, Joo-Hee Zo, Dae-Won Sohn
Journal: Circulation (2014)

Introduction: Patients with rheumatic mitral stenosis (RMS) and atrial fibrillation (AF) have revealed a high incidence of systemic embolism. Current guidelines do not recommend anticoagulation in patient with RMS and sinus rhythm. Hypothesis: The predictors of clinical events may facilitate adverse outcome in RMS patients with sinus rhythm. Methods: A total 1,019 patients who diagnosed with RMS were evaluated retrospectively between March 2003 and June 2013. Of these, patients with past or present AF (n = 447), who used anticoagulants or had prior thromboembolism (n = 154), or who performed mitral valve replacement within 9-month after diagnosis (n = 125) were excluded. A total of 293 patients were included. The clinical events were defined as all cause death and systemic embolism. Results: During the mean follow-up period of 68.2 ± 36.6 months, clinical events were developed in twenty-one patients (7.2%; embolism 12, all cause death 9) with 2.1% of average annual event rate. In the Cox-proportional hazard regression analysis, age was independent predictor of clinical events (HR 1.07 (95% CI 1.01-1.13), p = 0.026) after adjustment of confounding factors. LA dimension ≥ 47 mm showed borderline significance to predict events (HR 2.45 (95% CI 0.98 - 6.15), p = 0.057). Mitral valve area was not associated with events. In middle and old aged group (age ≥ 50), LA dimension ≥ 47 mm was a good prognosticator (HR 2.97 (95% CI 1.05 - 8.36), p = 0.040). During follow-up, sixty patients (20.5%) were developed AF with 3.5% annual event rate. LA dimension ≥ 47 mm was an independent predictor of composite all events including clinical events and development of AF. Conclusions: New onset AF was frequently developed in patients with RMS and sinus rhythm. Because of high risk of embolism of valvular AF, we need careful follow up in these patients group. In middle and old age group, enlarged LA dimension was closely related with all cause death or systemic embolism.
Abstract 11733: Assessment of Carotid Plaque Neovascularization Using Quantitative Analysis of Contrast-Enhanced Ultrasound Imaging is Useful for Risk Stratification in Patients With Coronary Artery Disease
Authors: Jun Nakamura, Takamitsu Nakamura, Juntaro Deyama, Daisuke Fujioka, Ken-ichi Kawabata, Jun-ei Obata, Kazuhiro Watanabe, Yosuke Watanabe, Kiyotaka Kugiyama
Journal: Circulation (2014)

Introduction: Extensive neovascularization in atherosclerotic plaque has been shown to be associated with plaque progression and instability, leading to atherosclerotic cardiovascular events. Contrast-enhanced ultrasound (CEUS) of the carotid artery is a potential technique for imaging plaque neovascularization. Hypothesis: Assessment of intra-plaque neovascularization of the carotid artery using quantitative analysis of CEUS provides prognostic information in patients with coronary artery disease (CAD). Methods: This study included 206 patients with stable CAD and with carotid intima-media thickness (IMT) &gt; 1.1 mm. They underwent a CEUS examination of the carotid artery and were followed-up prospectively for &lt; 38 months or until a cardiac event (cardiac death, non-fatal myocardial infarction [MI], unstable angina pectoris [uAP] requiring unplanned coronary revascularization, or heart failure requiring hospitalization). The degree of contrast signals measured within the carotid plaque after the intravenous injection of contrast material was quantified by calculating the increase in mean gray scale level within the region of interest of the carotid plaque, expressed as plaque enhanced intensity. Results: During the follow-up period (3 - 38 months, mean 22.8 ± 11.8 months), 31 events occurred (2 cardiac deaths, 7 non-fatal MIs, 16 uAP, and 6 heart failure). Multivariate Cox proportional hazards analysis showed that plaque enhanced intensity was a significant predictor of cardiac events independent of traditional risk factors (HR, 1.52; 95% CI, 1.20 - 1.94; p = 0.001). The addition of plaque enhanced intensity had a significant incremental effect on the area under the ROC curve (AUC) generated using baseline model of traditional risk factors (AUC: baseline model 0.69 vs. baseline model + plaque enhanced intensity 0.78, p = 0.03). The addition of the plaque enhanced intensity to the baseline risk factors resulted in net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (NRI 0.58, p = 0.003; and IDI 0.078, p = 0.03). Conclusions: The assessment of carotid plaque neovascularization using quantitative analysis of CEUS may be useful for risk stratification in patients with CAD.
Abstract 935: Exome sequencing reveals BRAF mutations in papillary craniopharyngiomas
Authors: Amaro N. Taylor-Weiner, Priscilla K. Brastianos, Peter E. Manley, Robert T. Jones, Dora Dias-Sangata, Aaron Thorner, Fausto Rodriguez, Lindsay Bernardo, Laura Schubert, Chip Stewart, Mark Keiran, William C. Hahn, Adam Resnick, David Louis, Sandro Sangata, Gad Getz
Journal: Cancer Research (2014)

Abstract Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain. Patients experience substantial clinical sequelae both from extension of the tumors and from therapeutic interventions which damage the optic chiasm, the pituitary stalk, and the hypothalamic area. Using whole exome sequencing we identified mutations in beta-catenin (CTNNB1) in nearly all adamantinomatous craniopharyngiomas (11/12; 92%) and recurrent mutations in BRAF (V600E) in all papillary craniopharyngiomas (3/3; 100%). Targeted genotyping revealed BRAF V600E in 95% of papillary craniopharyngiomas (36 of 39 tumors) and CTNNB1 mutation in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype and no other recurrent mutations or genomic aberrations were detected in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. Citation Format: Amaro N. Taylor-Weiner, Priscilla K. Brastianos, Peter E. Manley, Robert T. Jones, Dora Dias-Sangata, Aaron Thorner, Fausto Rodriguez, Lindsay Bernardo, Laura Schubert, Chip Stewart, Mark Keiran, William C. Hahn, Adam Resnick, David Louis, Sandro Sangata, Gad Getz. Exome sequencing reveals BRAF mutations in papillary craniopharyngiomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 935. doi:10.1158/1538-7445.AM2014-935